A Phex mutation in a murine model of X-linked hypophosphatemia alters phosphate responsiveness of bone cells
Open Access
- 17 October 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 27 (2) , 453-460
Abstract
Mutations in the PHEX gene cause X‐linked hypophosphatemia (XLH). Hypophosphatemia in XLH results from increased circulating levels of a phosphaturic hormone, fibroblast growth factor 23 (FGF23), which inhibits renal phosphate reabsorption and 1,25‐dihydroxyvitamin D (calcitriol) synthesis. The current standard therapy for XLH—high‐dose phosphate and calcitriol—further increases FGF23 concentrations, suggesting that patients with XLH may have an altered response to extracellular phosphate. To test for the presence of abnormal phosphate responsiveness, we compared serum biochemistries and femoral Fgf23 mRNA expression between wild‐type mice, murine models of XLH (PhexK496X) and hyperphosphatemic tumoral calcinosis (Galnt3−/−), and Galnt3/Phex double‐mutant mice. Phex mutant mice had not only increased Fgf23 expression but also reduced proteolytic cleavage of intact Fgf23 protein, resulting in markedly elevated intact Fgf23 levels and consequent hypophosphatemia. In contrast, despite markedly increased Fgf23 expression, Galnt3 knockout mice had significantly high proteolytic cleavage of Fgf23 protein, leading to low intact Fgf23 concentrations and hyperphosphatemia. Galnt3/Phex double‐mutant mice had an intermediate biochemical phenotype between wild‐type and Phex mutant mice, including slightly elevated intact Fgf23 concentrations with milder hypophosphatemia. Despite the hypophosphatemia, double‐mutant mice attempted to reduce serum phosphate back to the level of Phex mutant mice by upregulating Fgf23 expression as much as 24‐fold higher than Phex mutant mice. These data suggest that Phex mutations alter the responsiveness of bone cells to extracellular phosphate concentrations and may create a lower set point for “normal” phosphate levels. © 2012 American Society for Bone and Mineral ResearchKeywords
This publication has 40 references indexed in Scilit:
- Treatment of X-Linked Hypophosphatemia with Calcitriol and Phosphate Increases Circulating Fibroblast Growth Factor 23 ConcentrationsThe Journal of Clinical Endocrinology & Metabolism, 2010
- Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutationsAmerican Journal of Medical Genetics Part A, 2010
- Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formationProceedings of the National Academy of Sciences, 2009
- Effects of hPTH(1-34) Infusion on Circulating Serum Phosphate, 1,25-Dihydroxyvitamin D, and FGF23 Levels in Healthy MenJournal of Bone and Mineral Research, 2009
- Ablation of the Galnt3 Gene Leads to Low-Circulating Intact Fibroblast Growth Factor 23 (Fgf23) Concentrations and Hyperphosphatemia Despite Increased Fgf23 ExpressionEndocrinology, 2009
- Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patientsBone, 2008
- Calcimimetics as an Adjuvant Treatment for Familial Hypophosphatemic RicketsClinical Journal of the American Society of Nephrology, 2008
- A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosisJournal of Clinical Investigation, 2007
- FGF-23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate HomeostasisJournal of Bone and Mineral Research, 2004
- Osteomalacia in Hyp Mice Is Associated with Abnormal Phex Expression and with Altered Bone Matrix Protein Expression and DepositionEndocrinology, 2001